Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
复制标题
DOI：
10.1371/journal.pone.0121071
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Felip E
中科院分区：
文献类型：
--
作者：
Cedrés S;Ponce-Aix S;Zugazagoitia J;Sansano I;Enguita A;Navarro-Mendivil A;Martinez-Marti A;Martinez P;Felip E
恶性胸膜间皮瘤（MPM）发病率不断上升且预后不良，这就需要找到针对该疾病的有效治疗方法。PD1/PD - L1通路在肿瘤免疫逃逸中起着核心作用，并且似乎是预测性和预后性标志物。PD - L1在许多不同的人类癌症中都有表达，但其在MPM中的作用尚未确定。本研究的目的是评估PD - L1在MPM中的表达。
对2002年11月至2014年2月期间来自两家机构的119例MPM患者进行了回顾性研究。用抗PD - L1（克隆号E1L3N）对福尔马林固定、石蜡包埋的组织进行染色。肿瘤细胞中PD - L1表达超过1%的病例被视为阳性。
对77例有肿瘤组织的患者进行了PD - L1分析，其中20.7%的患者为阳性（14例在细胞膜表达，16例在细胞质表达，4例在免疫浸润细胞中表达）。PD - L1表达强度在56.2%的患者中为弱，25%为中等，18.7%为强。PD - L1表达与组织学类型之间存在显著关系（非上皮样肿瘤中PD - L1表达为37.5%，上皮样肿瘤中为13.2%；p = 0.033）。PD - L1阳性患者的中位生存期为4.79个月，而PD - L1阴性患者为16.3个月（p = 0.012）。
我们已经表明，20%的患者表达PD - L1，这与非上皮样组织学类型相关，且在MPM中预后不良。我们的研究结果表明，在选择免疫治疗患者时，PD - L1值得进一步探究。
The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM. 119 MPM patients (p) from two institutions between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N). Cases showing more than 1% of tumor cells expression of PD-L1 were considered positive. PD-L1 was analyzed in 77 p with tumor tissue available and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 4 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was a significant relationship between PD-L1 expression and histology (PD-L1 expression 37.5% in no-epithelioid tumor and 13.2% in epithelioid; p=0.033). The median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p=0.012). We have shown PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy.
登录
查看更多内容
影响因子：
11.5
作者：
Konishi, J;Yamazaki, K;Nishimura, M
通讯作者：
Nishimura, M
影响因子：
11.5
作者：
Ohigashi, Y;Sho, M;Nakajima, Y
通讯作者：
Nakajima, Y
DOI：
10.1097/jto.0000000000000177
发表时间：
2014-07
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Mansfield AS;Roden AC;Peikert T;Sheinin YM;Harrington SM;Krco CJ;Dong H;Kwon ED
通讯作者：
Kwon ED
影响因子：
3.4
作者：
Opitz, Isabelle;Soltermann, Alex;Weder, Walter
通讯作者：
Weder, Walter
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM